Hepatitis Forums

Hepatitis C Main Forums => Hepatitis C Research News & Studies => Topic started by: Hep Editors on July 03, 2019, 10:58:47 am

Title: Various Factors Tied to Lower Cure Rates for Epclusa And Mavyret
Post by: Hep Editors on July 03, 2019, 10:58:47 am
Researchers identified an array of factors associated with a lower likelihood of being cured of hepatitis C virus (HCV) through treatment with Mavyret (glecaprevir/pibrentasvir) or Epclusa (sofosbuvir/velpatasvir) in a recent real-world study.

Presenting their findings at the 53rd International Liver Congress in Vienna, researchers analyzed data on 1,131 people with HCV who began Mavyret between August 2017 and April 2018 and were included in the Trio Health disease management program. The study also included 777 people who began Epclusa (sofosbuvir/velpatasvir) treatment during the same period.

For more...
https://www.hepmag.com/article/various-factors-tied-lower-cure-rates-epclusa-mavyret